GARFIELD classifies disease-relevant changes in the genome

New approach reveals role of genomic changes in a disease, both within and outside genes

GARFIELD classifies disease-relevant changes in the genome

Using the GARFIELD tool, scientists can identify disease-associated regions of DNA in the genome, including those not located in genes
Using the GARFIELD tool, scientists can identify disease-associated regions of DNA in the genome, including those not located in genes

Researchers at the Wellcome Sanger Institute and EMBL’s European Bioinformatics Institute (EMBL-EBI) have developed a new approach to understand the functional effects of genetic variations associated with a disease, even if they aren't located in a gene. Using this approach could help scientists uncover previously unknown mechanisms that control gene activity and determine whether cell work normally or, in the case of genetic diseases, the cells malfunction. This knowledge will help drive new research and could identify new targets for drug development.

The tool, called GARFIELD, uses a computational approach known as functional enrichment. This approach combines the positions on the genome of disease-associated DNA changes with information on the role of those regions. In this way, the system highlights those variations that are known to produce changes in the activity of genes that are relevant to the disease being studied.

GARFIELD has been designed to take into account the major factors that could confuse the results of a study, and can include weak disease associations to increase its power for insight. Because of these measures, the system provides the widest information on the largest number of disease associations.

In a paper in Nature Genetics, the researchers detail how they used the method to analyse the disease associations already detailed in publicly available genome-wide association studies' summary statistics. They uncovered statistically significant associations for the majority of disease traits, and highlighted clear differences in the patterns of DNA changes associated with these different disease features. The findings both confirmed current understanding of key cellular types involved in, and also reveal new areas of the genome that had not previously been implicated in disease.

To make GARFIELD more accessible to the wider research community, the scientists have developed additional software to make the system easy to use. This includes building tools to visualise the results in a way that can show tens or thousands of potentially important disease associations in comprehensive and comprehensible way.

The standalone GARFIELD tool is available on the EMBL-EBI website and the GARFIELD R-package is available on Bioconductor.

Notes to Editors

Iotchkova V  et al. (2019). GARFIELD classifies disease-relevant genomic features through integration of functional annotations with association signals. Nature Genetics. Published online 28 January; DOI: 10.1038/s41588-018-0322-6

Selected Websites
Genome-wide association studiesStoriesGenome-wide association studies
Genome-wide association studies have led to the discovery of hundreds of genes with a role in common diseases. 

What is a complex disease?FactsWhat is a complex disease?
Many common diseases are influenced by a combination of multiple genes and environmental factors. These diseases are referred to as complex diseases.

Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
CB10 1SA,

Mobile +44 (0) 7748 379849

Recent News

Analysis of CRISPR-Cas9 datasets leads to largest genetic screen resource for cancer research
Study will help narrow down the list of targets for the next generation of cancer treatments
Researchers identify over 140 genes linked to immune system regulation
First extensive immune profiling of mice reveals a vast catalogue of genes that regulate the immune system and model human disease
Dr Konstantinos Tzelepis receives ASH–BSH Abstract Achievement Award for leukaemia target research
Award-winning abstract on METTL3 presented at American Society of Hematology meeting